Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05734105 | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib(INSIGHT) | active not recruiting | Phase 3 | 54 | Deciphera Pharmaceuticals, LLCINDUSTRY |
| 15 |
| Dec 17, 2025 |
| clinicaltrials |
| NCT06211036 | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab(DeLLphi-305) | active not recruiting | Phase 3 | 563 | AmgenINDUSTRY | 29 | Dec 17, 2025 | clinicaltrials |
| NCT06449586 | CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT | active not recruiting | Phase 3 | 250 | Ruijin HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04270409 | Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | active not recruiting | Phase 3 | 337 | SanofiINDUSTRY | 24 | Dec 12, 2025 | clinicaltrials |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy(COSMIC-312) | active not recruiting | Phase 3 | 837 | ExelixisINDUSTRY | 34 | Dec 11, 2025 | clinicaltrials |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | active not recruiting | Phase 3 | 423 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.(SOLO-1) | active not recruiting | Phase 3 | 450 | AstraZenecaINDUSTRY | 15 | Dec 10, 2025 | clinicaltrials |
| NCT02066220 | International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | active not recruiting | Phase 2 / Phase 3 | 360 | Universitätsklinikum Hamburg-EppendorfOTHER | 16 | Dec 4, 2025 | clinicaltrials |
| NCT05028348 | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | active not recruiting | Phase 3 | 117 | European Myeloma Network B.V.NETWORK | 4 | Dec 4, 2025 | clinicaltrials |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line(DOMENICA) | active not recruiting | Phase 3 | 260 | ARCAGY/ GINECO GROUPOTHER | 10 | Dec 4, 2025 | clinicaltrials |
| NCT02341989 | Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer(SWENOTECA-ABC) | active not recruiting | Phase 3 | 348 | St. Olavs HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06100367 | 11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours | active not recruiting | Phase 2 / Phase 3 | 100 | Changi General HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04193059 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer(PANSY) | active not recruiting | Phase 3 | 1,560 | Fudan UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03052608 | A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | active not recruiting | Phase 3 | 296 | PfizerINDUSTRY | 23 | Nov 25, 2025 | clinicaltrials |
| NCT07248670 | Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC | active not recruiting | Phase 3 | 252 | Chongqing University Cancer HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03703297 | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy(ADRIATIC) | active not recruiting | Phase 3 | 730 | AstraZenecaINDUSTRY | 19 | Nov 21, 2025 | clinicaltrials |
| NCT03829462 | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients(NEXT-REGIRI) | active not recruiting | Phase 3 | 377 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04514419 | Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | active not recruiting | Phase 3 | 408 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04537156 | Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | active not recruiting | Phase 3 | 9,327 | Xiamen UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT04565054 | Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC(ADAPTlate) | active not recruiting | Phase 3 | 1,260 | Women's Cancer Study Group GmbHOTHER | 3 | Nov 19, 2025 | clinicaltrials |
| NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 3 | 445 | AkesoINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05690945 | A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 606 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05945901 | A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 669 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT01223248 | Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | active not recruiting | Phase 3 | 220 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Nov 4, 2025 | clinicaltrials |
| NCT02107703 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer(MONARCH 2) | active not recruiting | Phase 3 | 669 | Eli Lilly and CompanyINDUSTRY | 20 | Oct 21, 2025 | clinicaltrials |
| NCT03529110 | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] | active not recruiting | Phase 3 | 524 | Daiichi SankyoINDUSTRY | 15 | Oct 21, 2025 | clinicaltrials |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer(LIBRETTO-431) | active not recruiting | Phase 3 | 261 | Eli Lilly and CompanyINDUSTRY | 26 | Oct 21, 2025 | clinicaltrials |
| NCT05468489 | To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC | active not recruiting | Phase 3 | 200 | Shanghai Henlius BiotechINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | active not recruiting | Phase 3 | 228 | DualityBio Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma(ZUMA-22) | active not recruiting | Phase 3 | 231 | Kite, A Gilead CompanyINDUSTRY | 7 | Oct 15, 2025 | clinicaltrials |
| NCT02685605 | Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme(INTRAGO-II) | active not recruiting | Phase 3 | 314 | Universitätsmedizin MannheimOTHER | 8 | Oct 14, 2025 | clinicaltrials |
| NCT02767804 | eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | active not recruiting | Phase 3 | 290 | Xcovery Holdings, Inc.INDUSTRY | 20 | Oct 14, 2025 | clinicaltrials |
| NCT04365374 | Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study) | active not recruiting | Phase 3 | 230 | GT Medical Technologies, Inc.INDUSTRY | 1 | Oct 7, 2025 | clinicaltrials |
| NCT03057054 | Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 3 | 173 | Children's Oncology GroupNETWORK | 2 | Oct 6, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05840211 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy(ASCENT-07) | active not recruiting | Phase 3 | 654 | Gilead SciencesINDUSTRY | 28 | Oct 3, 2025 | clinicaltrials |
| NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2(REGAL) | active not recruiting | Phase 3 | 127 | Sellas Life Sciences GroupINDUSTRY | 10 | Oct 1, 2025 | clinicaltrials |
| NCT02505750 | Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma(OPERA) | active not recruiting | Phase 3 | 148 | Centre Antoine LacassagneOTHER | 3 | Sep 29, 2025 | clinicaltrials |
| NCT05980481 | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | active not recruiting | Phase 2 / Phase 3 | 201 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05020769 | SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. | active not recruiting | Phase 2 / Phase 3 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02194842 | Phase III Radium 223 mCRPC-PEACE III(PEACE III) | active not recruiting | Phase 3 | 446 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Sep 19, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT04547504 | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %(PERSEE) | active not recruiting | Phase 3 | 349 | University Hospital, BrestOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT02716233 | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents(CAALL-F01) | active not recruiting | Phase 3 | 2,044 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04335669 | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | active not recruiting | Phase 3 | 325 | Lund University HospitalOTHER | 2 | Sep 12, 2025 | clinicaltrials |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(COSMIC-313) | active not recruiting | Phase 3 | 855 | ExelixisINDUSTRY | 25 | Sep 10, 2025 | clinicaltrials |
| NCT04919226 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE(COMPOSE) | active not recruiting | Phase 3 | 259 | ITM Solucin GmbHINDUSTRY | 10 | Sep 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 18, 2025source: clinicaltrials